Orion Oyj Past Earnings Performance
Past criteria checks 2/6
Orion Oyj has been growing earnings at an average annual rate of 7%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 5.3% per year. Orion Oyj's return on equity is 24.4%, and it has net margins of 18.2%.
Key information
7.0%
Earnings growth rate
7.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 5.3% |
| Return on equity | 24.4% |
| Net Margin | 18.2% |
| Next Earnings Update | 25 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Orion Oyj makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,190 | 217 | 299 | 127 |
| 30 Sep 23 | 1,163 | 173 | 289 | 131 |
| 30 Jun 23 | 1,354 | 306 | 302 | 139 |
| 31 Mar 23 | 1,348 | 336 | 288 | 136 |
| 31 Dec 22 | 1,341 | 350 | 284 | 133 |
| 30 Sep 22 | 1,323 | 351 | 278 | 136 |
| 30 Jun 22 | 1,072 | 202 | 252 | 123 |
| 31 Mar 22 | 1,043 | 192 | 246 | 124 |
| 31 Dec 21 | 1,041 | 194 | 238 | 118 |
| 30 Sep 21 | 1,020 | 187 | 231 | 115 |
| 30 Jun 21 | 1,029 | 192 | 235 | 118 |
| 31 Mar 21 | 1,067 | 212 | 235 | 122 |
| 31 Dec 20 | 1,078 | 220 | 245 | 123 |
| 30 Sep 20 | 1,097 | 240 | 254 | 118 |
| 30 Jun 20 | 1,131 | 260 | 258 | 121 |
| 31 Mar 20 | 1,090 | 225 | 265 | 120 |
| 31 Dec 19 | 1,051 | 200 | 264 | 119 |
| 30 Sep 19 | 1,039 | 209 | 255 | 114 |
| 30 Jun 19 | 977 | 172 | 250 | 110 |
| 31 Mar 19 | 971 | 187 | 244 | 105 |
| 31 Dec 18 | 978 | 197 | 238 | 104 |
| 30 Sep 18 | 981 | 198 | 237 | 103 |
| 30 Jun 18 | 1,001 | 206 | 236 | 102 |
| 31 Mar 18 | 1,015 | 206 | 238 | 101 |
| 31 Dec 17 | 1,034 | 219 | 237 | 99 |
| 30 Sep 17 | 1,048 | 212 | 244 | 111 |
| 30 Jun 17 | 1,065 | 242 | 246 | 114 |
| 31 Mar 17 | 1,077 | 253 | 245 | 118 |
| 31 Dec 16 | 1,074 | 249 | 243 | 118 |
| 30 Sep 16 | 1,055 | 241 | 235 | 112 |
| 30 Jun 16 | 1,036 | 214 | 233 | 108 |
| 31 Mar 16 | 1,018 | 206 | 232 | 108 |
| 31 Dec 15 | 1,016 | 208 | 235 | 108 |
| 30 Sep 15 | 1,009 | 210 | 237 | 105 |
| 30 Jun 15 | 1,009 | 214 | 237 | 103 |
| 31 Mar 15 | 1,030 | 224 | 237 | 105 |
| 31 Dec 14 | 1,015 | 211 | 235 | 106 |
| 30 Sep 14 | 1,033 | 226 | 240 | 108 |
| 30 Jun 14 | 1,031 | 226 | 242 | 108 |
| 31 Mar 14 | 1,003 | 203 | 245 | 104 |
| 31 Dec 13 | 1,007 | 206 | 248 | 102 |
| 30 Sep 13 | 989 | 193 | 245 | 104 |
| 30 Jun 13 | 998 | 201 | 249 | 109 |
Quality Earnings: ORIN.F has a high level of non-cash earnings.
Growing Profit Margin: ORIN.F's current net profit margins (18.2%) are lower than last year (26.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ORIN.F's earnings have grown by 7% per year over the past 5 years.
Accelerating Growth: ORIN.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ORIN.F had negative earnings growth (-38%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-6.8%).
Return on Equity
High ROE: ORIN.F's Return on Equity (24.4%) is considered high.